This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with moderate-to-severe asthma.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
200
subcutaneous injection
subcutaneous injection
The First Clinical Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
RECRUITINGChange from the baseline in Forced Expiratory Volume in one second (FEV1)
Change from baseline in pre-bronchodilator FEV1 in each dose group at 12 weeks of CM512 treatment compared with placebo.
Time frame: Up to week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.